

EXHIBIT 68

**TO DECLARATION OF WENDY L. DEVINE
IN SUPPORT OF NUVASIVE, INC.'S
OPPOSITION TO DEFENDANTS' MOTION
FOR SUMMARY JUDGMENT OR, IN THE
ALTERNATIVE, SUMMARY
ADJUDICATION**

Alphatec Holdings Q4 2017 Financial Results and SafeOp Acquisition Call

V4 March 7, 2018

Executives

Pat Miles – Chairman and Chief Executive Officer

Terry Rich – President and Chief Operating Officer

Jeff Black – Chief Financial Officer

Disclosures/ Opening Statement (Carol Ruth, TRG)

Thank you. Good afternoon, and welcome to Alphatec Holdings' fourth quarter and full year 2017 conference call. We would like to remind everyone that participants on the call will make forward-looking statements. These statements are based on current expectations and are subject to uncertainties that could cause actual results to differ materially. These uncertainties are detailed in documents filed regularly with the SEC.

During this call, you may hear the Company refer to reported amounts, which are in accordance with U.S. GAAP, as well as non-GAAP or pro forma measures. Reconciliations of non-GAAP measures to U.S. GAAP can be found in the supplemental financial tables included in the press release, which identify and quantify all excluded items and provide management's view of why this information is useful to investors.

Joining us on the call today will be Alphatec's Chairman and CEO, Pat Miles; President and COO, Terry Rich and CFO, Jeff Black.

Now, I will turn the call over to Terry Rich.

Based upon the current configuration, we are excited to utilize the advanced, automated SSEP technology in surgery. The advanced modality received FDA clearance in 2014. We expect to receive clearance for automated EMG's in Q4 of this year, and to launch the combined platform as part of our spine surgery architecture early in 2019.

Formatted: Indent: First line: 0.5"

3. Finally, I will turn to how the SafeOp technology and team will fit with into the ATEC family, ~~and enable us to offer comprehensive procedural solutions~~. Our new leadership team has been devised with industry-leading spine and market-making expertise. Through these ~~the addition of our new adjunctive technology team additions~~ in Richard O'Brien, Rob Snow, and Jim Gharib, it is without argument that Alphatec ATEC has industry-leading ~~obtains industry-leading~~ neurophysiology expertise, which will significantly expand our internal know-how and accelerate our ability to create end-to-end procedural solutions.

Formatted: Indent: First line: 0.5", No bullets or numbering

Today, we also announced a key appointment, which I'm thrilled to share. I am honored to welcome Dr. Luiz Pimenta, one of spine's most celebrated innovators, to Alphatec ATEC in his role as ~~the role of~~ Chief Medical Officer. As many of you know, Dr. Pimenta is widely credited with pioneering new surgical techniques and developing technologies to improve spine surgery. I started partnering ~~ed~~ closely with him over a decade ago to develop and popularize lateral surgery, which is now an over \$500 million market. And I cannot wait to continue to work together to ~~continue to advance outcome-focused spine innovation~~ get back to innovating with him again.

Formatted: Indent: First line: 0.5"

Comment [TJ3]: Is he on the XLIF patent?

In conclusion, the excitement about our new vision, ~~both internally and increasingly, externally, is~~ around ATEC is absolutely electric; an almost complete reversal from how this company was perceived only 12 months ago. I am exceptionally proud of where we stand in terms of unity of direction ~~direction~~, motivation, and spine and neurophysiology ~~expertise~~. We have certainly laid the foundation for growth! Now, we are prioritizing the initiatives that will enable us to continue to make progress against our vision for predictable, sustained ~~able~~ growth. I have no doubt that this company will ultimately command a much greater share of the spine market than it does today. I am